Morpholino

MO2-trdn

ID

ZDB-MRPHLNO-230525-1

Name

MO2-trdn

Previous Names

None

Target

Sequence

5' - TCCATCTCTCTCATGCACTAACAGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

Translation-blocking MO.

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO2-trdn

No data available

Phenotype

Phenotype resulting from MO2-trdn

No data available

Phenotype of all Fish created by or utilizing MO2-trdn

Phenotype	Fish	Conditions	Figures
heart contraction rate of continuous process, ameliorated	WT + MO2-trdn + MO3-trdn	chemical treatment by environment: adrenaline	Figure 4 from Vecchi et al., 2021
post-vent region curved, abnormal	WT + MO2-trdn + MO3-trdn	control	Figure 2 from Vecchi et al., 2021
heart contraction rate of continuous process, exacerbated	WT + MO2-trdn + MO3-trdn	chemical treatment by environment: flecainide	Figure 4 from Vecchi et al., 2021
heart contraction rate of continuous process, ameliorated	WT + MO2-trdn + MO3-trdn	chemical treatment by environment: isoprenaline	Figure 4 from Vecchi et al., 2021
heart contraction decreased rate of continuous process, abnormal	WT + MO2-trdn + MO3-trdn	control	Figure 4 from Vecchi et al., 2021
heart contraction decreased rate of continuous process, abnormal	WT + MO2-trdn + MO3-trdn	chemical treatment by environment: metoprolol	Figure 4 from Vecchi et al., 2021
trunk curved, abnormal	WT + MO2-trdn + MO3-trdn	control	Figure 2 from Vecchi et al., 2021
heart contraction decreased rate of continuous process, abnormal	WT + MO2-trdn + MO3-trdn	chemical treatment by environment: atropine	Figure 4 from Vecchi et al., 2021
pericardium edematous, abnormal	WT + MO2-trdn + MO3-trdn	control	Figure 2 from Vecchi et al., 2021

Citations